As for other GLP-1 RAs such as dulaglutide, albiglutide, and lixisenatide, data based on trials solely investigating the effects of these drugs on weight loss in patients with obesity is scarce; however, an abundance of trials have tested the CV effects of these drugs in patients with diabetes. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.